VolitionRX Limited (NYSEAMERICAN:VNRX) Short Interest Up 46.6% in February

VolitionRX Limited (NYSEAMERICAN:VNRX) saw a significant increase in short interest in the month of February. As of February 13th, there was short interest totaling 2,294,782 shares, an increase of 46.6% from the January 29th total of 1,565,335 shares. Based on an average daily trading volume, of 2,140,767 shares, the days-to-cover ratio is currently 1.1 days. Currently, 1.9% of the company’s shares are short sold. Currently, 1.9% of the company’s shares are short sold. Based on an average daily trading volume, of 2,140,767 shares, the days-to-cover ratio is currently 1.1 days.

VolitionRX Stock Down 9.4%

Shares of VNRX stock traded down $0.02 during trading hours on Friday, reaching $0.21. 1,282,495 shares of the stock traded hands, compared to its average volume of 2,304,187. The firm has a market capitalization of $28.88 million, a PE ratio of -0.93 and a beta of 1.29. VolitionRX has a 1-year low of $0.17 and a 1-year high of $0.94. The business has a fifty day moving average price of $0.26 and a 200 day moving average price of $0.41.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.